The Evaluation and Management of Lung Metastases in Patients with Giant Cell Tumors of Bone in the Denosumab Era
In this study, we conducted a meta-analysis of the contemporary literature to evaluate all management strategies for GCTB metastases. A combination of the terms "lung metastases", "giant cell tumor", "bone", "treatment", and "oncologic outcomes" returned 133 patients meeting our inclusion criteria: 64 males and 69 females, with a median age of 28 years (7-63), at the onset of primary GCTB. Lung metastases typically occur at a mean interval of 26 months (range: 0-143 months) after treatment of the primary site, commonly presenting as multiple and bilateral lesions. Various treatment approaches, including surgery, chemothera...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Giulia Trovarelli Arianna Rizzo Mariachiara Cerchiaro Elisa Pala Andrea Angelini Pietro Ruggieri Source Type: research
Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update
Curr Oncol. 2024 Apr 8;31(4):2112-2132. doi: 10.3390/curroncol31040157.ABSTRACTCurettage is recommended for the treatment of Campanacci stages 1-2 giant cell tumor of bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab treatment. In the distal femur, bone chips and plate fixation are utilized to reduce damage to the subchondral bone and prevent pathological fracture, respectively. For local recurrence, re-curettage may be utilized when feasible. En bloc resection is an option for very aggressive Campanacci stage 3 GCTB in the extremities, pelvis, sacrum, and spine, combined with 1-3 do...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Shinji Tsukamoto Andreas F Mavrogenis Tomoya Masunaga Kanya Honoki Hiromasa Fujii Akira Kido Yasuhito Tanaka Costantino Errani Source Type: research
The Evaluation and Management of Lung Metastases in Patients with Giant Cell Tumors of Bone in the Denosumab Era
In this study, we conducted a meta-analysis of the contemporary literature to evaluate all management strategies for GCTB metastases. A combination of the terms "lung metastases", "giant cell tumor", "bone", "treatment", and "oncologic outcomes" returned 133 patients meeting our inclusion criteria: 64 males and 69 females, with a median age of 28 years (7-63), at the onset of primary GCTB. Lung metastases typically occur at a mean interval of 26 months (range: 0-143 months) after treatment of the primary site, commonly presenting as multiple and bilateral lesions. Various treatment approaches, including surgery, chemothera...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Giulia Trovarelli Arianna Rizzo Mariachiara Cerchiaro Elisa Pala Andrea Angelini Pietro Ruggieri Source Type: research
Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update
Curr Oncol. 2024 Apr 8;31(4):2112-2132. doi: 10.3390/curroncol31040157.ABSTRACTCurettage is recommended for the treatment of Campanacci stages 1-2 giant cell tumor of bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab treatment. In the distal femur, bone chips and plate fixation are utilized to reduce damage to the subchondral bone and prevent pathological fracture, respectively. For local recurrence, re-curettage may be utilized when feasible. En bloc resection is an option for very aggressive Campanacci stage 3 GCTB in the extremities, pelvis, sacrum, and spine, combined with 1-3 do...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Shinji Tsukamoto Andreas F Mavrogenis Tomoya Masunaga Kanya Honoki Hiromasa Fujii Akira Kido Yasuhito Tanaka Costantino Errani Source Type: research
The Evaluation and Management of Lung Metastases in Patients with Giant Cell Tumors of Bone in the Denosumab Era
In this study, we conducted a meta-analysis of the contemporary literature to evaluate all management strategies for GCTB metastases. A combination of the terms "lung metastases", "giant cell tumor", "bone", "treatment", and "oncologic outcomes" returned 133 patients meeting our inclusion criteria: 64 males and 69 females, with a median age of 28 years (7-63), at the onset of primary GCTB. Lung metastases typically occur at a mean interval of 26 months (range: 0-143 months) after treatment of the primary site, commonly presenting as multiple and bilateral lesions. Various treatment approaches, including surgery, chemothera...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Giulia Trovarelli Arianna Rizzo Mariachiara Cerchiaro Elisa Pala Andrea Angelini Pietro Ruggieri Source Type: research
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
CONCLUSION: The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or 'bone builders' in patients with very high or imminent risk of fracture.PMID:38654732 | PMC:PMC11036926 | DOI:10.1177/1759720X241234584 (Source: Adv Data)
Source: Adv Data - April 24, 2024 Category: Epidemiology Authors: Angelo Fassio Davide Gatti Annalisa Biffi Raffaella Ronco Gloria Porcu Giovanni Adami Rosaria Alvaro Riccardo Bogini Achille P Caputi Luisella Cianferotti Bruno Frediani Stefano Gonnelli Giovanni Iolascon Andrea Lenzi Salvatore Leone Raffaella Michieli Si Source Type: research
Denosumab-induced bone changes in a child: a case report
We present the case of a 9-year-old girl who developed striking bone changes following two years of denosumab therapy for giant cell lesions of the jaw. (Source: Pediatric Radiology)
Source: Pediatric Radiology - April 20, 2024 Category: Radiology Source Type: research
FDA Approves New Biosimilars to Denosumab with an Interchangeable Designation
The FDA has approved the first interchangeable biosimilars for denosumab. (Source: The Rheumatologist)
Source: The Rheumatologist - April 18, 2024 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Biologics/DMARDs Conditions Drug Updates Osteoarthritis and Bone Disorders denosumab denosumab-bbdz Jubbonti Prolia Wyost Xgeva Source Type: research
Denosumab ‐induced autoimmune hepatitis: Case report
This report described a patient not known to have a hepatic disease, found to have a drug-induced autoimmune hepatitis from denosumab. This is an unreported side effect, and here, we presented the possible predisposing factors and suggested monitoring parameters. (Source: Clinical Case Reports)
Source: Clinical Case Reports - April 17, 2024 Category: General Medicine Authors: Jawaher J. Alotaibi,
Bushra Albuqami,
Wadha Alotaibi,
Rawan M. Al Ghamdi,
Mohammed Alaskar,
Hadi Kuriry,
Nasser Almasri Tags: CASE REPORT Source Type: research
The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis
ConclusionThe utilization of lower cost osteoporosis medications such as oral bisphosphonates and estrogen hormonal therapy as PPF prophylaxis in this patient population would be economically viable if they reduce the PPF rate by 1.8% and 1.5%, respectively. For IV bisphosphonates and newer agents to be economically viable as PPF prophylaxis in the USA, their costs need to be significantly reduced. (Source: Osteoporosis International)
Source: Osteoporosis International - April 15, 2024 Category: Orthopaedics Source Type: research
Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review
We report the case of a female who developed significant delayed hypercalcaemia after teriparatide treatment for osteoporosis and review other cases in the literature to date.Case reportA 72-year-old female on teriparatide for the treatment of osteoporosis was found to have hypercalcaemia (3.30 mmol/l) on routine testing approximately 3 months after starting therapy. Serum calcium pretreatment was normal at 2.39 mmol/l. She was admitted to the hospital for investigations which identified a serum 25-hydroxyvitamin D of 94 nmol/l, a low parathyroid hormone of 6.0 pg/ml, and normal test results for 1,25 dihydroxyvitamin D (11...
Source: Osteoporosis International - April 13, 2024 Category: Orthopaedics Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Zoledronate after denosumab discontinuation: Is repeated administrations more effective than single infusion?
CONCLUSIONS: In patients with uncontrolled CTX levels after Dmab withdrawal, two ZOL infusions at 6 months apart do not prevent BMD loss and FX.PMID:38609157 | DOI:10.1210/clinem/dgae224 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Giorgia Grassi Alberto Ghielmetti Marta Zampogna Iacopo Chiodini Maura Arosio Giovanna Mantovani Cristina Eller Vainicher Source Type: research
